Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2994 • 2017 ACR/ARHP Annual Meeting
Improving Outcomes Using a Treat to Target Approach and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis
Lisa Buckley¹, Eileen Ware², Genna Kreher², Lisa Wiater¹, Jay Mehta¹ and Jon (Sandy) Burnham¹, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Office of Clinical Quality Improvement, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Polyarticular juvenile idiopathic arthritis (Poly-JIA) causes pain, functional disability, and joint damage. Variation in Poly-JIA clinical assessment and treatment likely has a negative…
Abstract Number: 2294 • 2017 ACR/ARHP Annual Meeting
Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis
Emily A. Smitherman¹, Janalee Taylor², Esi M. Morgan¹ and C. April Bingham³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatrics, Penn State College of Medicine, Hershey, PA
Background/Purpose: Despite modern treatment options for patients with juvenile idiopathic arthritis (JIA), rates of clinical inactive disease (CID) remain low. The Pediatric Rheumatology Care and…
Abstract Number: 2295 • 2017 ACR/ARHP Annual Meeting
Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality
Jacopo Agnolucci¹, Maria Elisabetta Zannin¹, Giorgia Martini¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Methotrexate (MTX) is the most used immunomodulatory drug in Juvenile Idiopathic Arthritis-associated uveitis (JIA-U) although its efficacy has been shown only in retrospective studies…
Abstract Number: 2297 • 2017 ACR/ARHP Annual Meeting
Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients
Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Inmaculada Calvo², Mª Isabel González-Fernández³, Berta Lopez Montesinos³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁴, Olga Maiz-Alonso⁵, Ana Blanco⁶, Antonio Atanes⁷, Beatriz Bravo⁸, Consuelo Modesto⁹, Gisela Díaz-Cordovés¹⁰, Miguel Cordero-Coma¹¹, David Diaz-Valle¹², Carlos Fernández-Cid¹³, Juan Cruz¹⁴, Oscar Ruiz Moreno¹⁵, MC Gonzalez-Vela¹⁶, Rosalía Demetrio-Pablo¹⁷, Nuria Vegas-Revenga¹, Carlos Fernández-Díaz¹, Jose L. Hernández¹⁸, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Pediatric Rheumatology, Rheumatology. Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ³Rheumatology. Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ⁶Ophtamology. Hospital Donostia. San Sebastian. Spain, San Sebastian, Spain, ⁷Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ⁸Rheumatology. Hospital Universitario Virgen de las Nieves. Granada. Spain, Granada, Spain, ⁹Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ¹⁰Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹³Ophtalmology. Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ¹⁴Rheumatology. Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ¹⁵Ophthalmology and Rheumatology., Ophtalmology. Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹⁶Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Uveitis is a severe manifestation of Juvenil Idiopathic Arthritis (JIA). Systemic treatment is based on conventional immunosuppresants. Anti-TNFa are used in refractory cases, mainly…
Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Katherine Roshak¹, Joan M Sopczynski², Ricardo Suehiro² and Lisa Marshall¹, ¹Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ²Pfizer, Collegeville, PA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…
Abstract Number: 2302 • 2017 ACR/ARHP Annual Meeting
The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich⁴, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal and Dermatology Research, Faculty of Medicine, Biology and Health, United Kingdom, University of Manchester, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Information regarding longer-term outcomes in JIA largely pre-date the introduction of biologic therapies and have been cross-sectional. The aim of this analysis was to…
Abstract Number: 1259 • 2017 ACR/ARHP Annual Meeting
Perspectives of Young People with Juvenile Idiopathic Arthritis, Their Caregivers, and Health Care Providers on Transition to Adult Care: Informing Development of a Transition Toolkit
Nadia Luca¹, Evelyn Rozenblyum², April Elliott³, Lynn R. Spiegel⁴, Nicole Johnson⁵, Sara Ahola Kohut⁶, Yvonne Brandelli³, Carolyn Johns⁷, Stephanie Luca⁸, Dianne P. Mosher⁹, Gordon Soon¹⁰, Karine Toupin-April¹¹, Gabriela Uifalusi³ and Jennifer N. Stinson¹², ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Royal University Hospital, Saskatoon, SK, Canada, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Med, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Transition from pediatric to adult care is an important process for adolescents and young adults with Juvenile Idiopathic Arthritis (JIA). A seamless transition is…
Abstract Number: 2305 • 2017 ACR/ARHP Annual Meeting
Efficacy of Function-Based Exercise Program on Functional Ability, Pain and Quality of Life in Children with Juvenile Idiopathic Arthritis
Ela Tarakci¹, Saime Nilay Baydogan¹, Sezgin Sahin², Amra Adrovic², Kenan Barut² and Ozgur Kasapcopur², ¹Istanbul University, Faculty of Health Science, Division of Physiotherapy and Rehabilitation, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children. Children with JIA,…
Abstract Number: 1739 • 2017 ACR/ARHP Annual Meeting
Vδ1, Vδ2, and Other γδT Cells in Blood and Synovium of Rheumatoid Arthritis and Other Autoimmune Arthritides
Anna Helena Jonsson¹, Michael Gurish¹, Lauren Henderson², Peter Nigrovic¹ and Michael Brenner³, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Innate-like T cells comprise on average 10-15% of peripheral T cell and have T-cell receptors (TCRs) that engage ligands other than classic HLA class…
Abstract Number: 2314 • 2017 ACR/ARHP Annual Meeting
Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?
Caterina Politi¹, Vanessa Cecchin¹, Fabio Vittadello¹, Alessandra Meneghel², Giorgia Martini¹ and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Oligoarticular Juvenile Idiopathic Arthritis (oligoJIA) is the most common JIA subtype. According with the most recent classification criteria1, monoarticular JIA (monoJIA) is included in…
Abstract Number: 1800 • 2017 ACR/ARHP Annual Meeting
Do Patient Reported Outcome Measurement Information System (PROMIS) Computer Adaptive Tests Correlate with Disease Activity in Juvenile Idiopathic Arthritis?
Rebecca Trachtman¹, Elizabeth T. Murray², Jackie Szymonifka³, Alexa Adams⁴, Nancy Pan⁴, Sarah Taber⁴, Thomas J. A. Lehman⁴, Karen Onel⁴ and Lisa A. Mandl⁵, ¹Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁵Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: The importance of patient-reported outcomes is increasingly recognized both in clinical care and in research. PROMIS is an NIH-supported collection of patient-reported outcome measures,…
Abstract Number: 2315 • 2017 ACR/ARHP Annual Meeting
Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Michael Miller¹, Yufan Yan² and George Lales³, ¹Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is associated with symptoms of anxiety and depression. We studied these symptoms and other health related quality of life (HRQOL)…
Abstract Number: 2270 • 2017 ACR/ARHP Annual Meeting
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet V. Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson¹, Heinrike Schmeling⁶, Jordi Anton⁷, Kirsten Minden⁸, Joy Hsu⁹, Kamal Bharucha¹⁰, Sunethra Wimalasundera¹¹, Alysha K. Kadva¹⁰, Ruchi Upmanyu¹¹, Navita L. Mallalieu⁹, Wendy Douglass¹¹, Daniel J Lovell¹ and Fabrizio De Benedetti¹², ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, ⁷Hospital Sant Joan de Deu, Barcelona, Spain, ⁸Charité – University of Medicine Berlin, Berlin, Germany, ⁹Roche Innovation Center, New York, NY, ¹⁰Genentech, South San Francisco, CA, ¹¹Roche Products, Ltd., Welwyn Garden City, United Kingdom, ¹²Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA)…
Abstract Number: 2322 • 2017 ACR/ARHP Annual Meeting
Quantitative Proteomics Comparison of Children with Inactive and Active Uveitis
Sheila Angeles-Han¹, Duc Duong², Steven Yeh³, Purnima Patel⁴, Virginia Miraldi Utz⁵, Kirsten Jenkins⁶, Danielle Lowe⁷, Sampath Prahalad⁸ and Gary Holland⁹, ¹Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ²Emory University, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁹Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with chronic non-infectious uveitis are at high risk for sight-threatening complications and vision loss. No biomarker predicts uveitis development or treatment response. Aqueous…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…

« Previous Page
1
…
7
8
9
10
11
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].